---
schema_version: "secwatch.filing_event.v1"
accession: "0001326190-22-000010"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T22:30:00.505488+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Altimmune Q3 net loss $23.5M, cash $201.9M; pemvidutide NAFLD data mid-Dec, obesity interim Q1 2023

## Summary
- Net loss of $23.5M ($0.48 per share) vs $33.5M loss YoY; revenue minimal at ~$0.
- Cash, equivalents & short-term investments totaled $201.9M at September 30, 2022.
- Topline 24-week data from Phase 1b NAFLD trial expected mid-December 2022.
- Interim 24-week readout from Phase 2 MOMENTUM obesity trial (~160 subjects) expected Q1 2023.
- Enrollment complete in Phase 1b type 2 diabetes trial; data readout expected Q1 2023.

## SEC filing metadata
- accession: 0001326190-22-000010
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000132619022000010/0001326190-22-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000132619022000010/alt-20221110x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326190-22-000010
- JSON: https://secwatch.observer/filing/0001326190-22-000010.json
- Plain text: https://secwatch.observer/filing/0001326190-22-000010.txt

## Key facts
- Earnings Releases
  Altimmune, Inc. reported financial results for three months ended September 30, 2022.
  - Period: three months ended September 30, 2022
  - Result: reported results
  source text: Revenue was minimal for the three months ended September 30, 2022 compared to $0.2 million in the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326190/000132619022000010/0001326190-22-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.